Safety coverage on Peptide News Digest pulls in the FAERS signals, label updates, contamination reports, post-market trial readouts, and the peptide-clinic enforcement actions that produce real harm.
The most active threads in 2025 and 2026: the Ozempic MDL (3,363 cases over alleged gastroparesis and other injuries before Judge Karen Marston in EDPA, with Daubert and summary judgment deadlines in late April), unregulated research-peptide contamination at peptide clinics and medspas, the University of Colorado secret-shopper study showing peptide vendors that kept selling after FDA warning letters, and a Medscape FAERS analysis showing different AE profiles across GLP-1 drugs.
For drug-specific safety, see #peptide-safety, #drug-safety, #semaglutide, or #tirzepatide. This tag covers the cross-cutting cases.
A 2026 chemistry study documented that when tirzepatide is compounded with vitamin B12 (a common differentiating additive used by compounding pharmacies to distinguish compounded products from the FDA-approved Mounjaro and Zepbound Eli Lilly formulations), the two substances can chemically bond and form a new molecule not present in the FDA-approved drug product. The finding adds to the accumulating pharmacovigilance case against compounded GLP-1 formulations, which are marketed as bioequivalent to the branded products but frequently contain non-FDA-approved additives whose long-term safety, immunogenicity, and pharmacokinetic profiles have not been characterized in registered clinical trials. Compounding-pharmacy additives often introduce impurities and reaction products that differ from the branded label chemistry. The chemistry-specific finding on tirzepatide + B12 bonding is the type of documented novel-molecule outcome that FDA safety scientists cited in the underlying rationale for the April 30, 2026 proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List. FDA Adverse Event Reporting System (FAERS) data as of July 2026: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide. The FDA 503B comment period on the exclusion closed Thursday July 30, 2026.
The full TRIUMPH-1 safety dataset clarified the retatrutide dysesthesia signal: 20.9% of patients on 12 mg reported tingling, tenderness, or altered sensation, versus 8.8% at 9 mg and 0.7% on placebo. The signal is dose-dependent, generally mild to moderate, and Lilly says it is being monitored across all ongoing TRIUMPH trials. The data sit alongside the arrhythmia signal (7/403 retatrutide, 3 MACE versus 0 placebo) that STAT flagged on June 6 and now constitute the field's main retatrutide-specific safety conversation.
STAT reported June 6 that new safety data presented at ADA showed seven of 403 retatrutide-treated patients experienced arrhythmias and three had major cardiovascular events, compared with none in the placebo group. The signal had been a watch item ahead of ADA because retatrutide adds glucagon-receptor activity to GLP-1 and GIP, raising heart-rate and energy-expenditure mechanisms that have not appeared in the same way for semaglutide or tirzepatide. Lilly's larger TRIUMPH-OUTCOMES cardiovascular trial reads out in 2027.
A Bloomberg opinion piece published April 21 argues that the FDA's planned July 23-24 PCAC review of seven peptides (BPC-157, MOTS-c, KPV, among others) and RFK Jr.'s broader push to reclassify 14 of 19 Category 2 peptides doesn't give consumers the evidence-based safety and efficacy data they need. The piece frames the ongoing compounding debate as a consumer-protection gap that clinical trial evidence — not political reclassification — should fill.
The Washington Post framed the FDA's upcoming July peptide panel through the lens of the exploding wellness craze, noting peptides are pitched as quick fixes for muscle building, injury healing, and anti-aging with minimal supporting research. When the FDA added 19 peptides to its restricted list in 2023, it cited safety risks including cancer and liver, kidney, and heart problems — concerns that have not been resolved.
CNN published a comprehensive consumer guide distinguishing FDA-approved peptide therapeutics from unregulated wellness peptides. Experts warn that rising demand is fueling an online black market with unknown safety risks, while HHS Secretary RFK Jr. pushes to relax restrictions.
The Week reports that India's GLP-1 market is surging following semaglutide patent expiry in March, with doctors warning that self-medication — particularly through unapproved online channels — poses serious risks including pancreatitis and thyroid complications. Experts emphasize the need for clinical oversight and proper dose titration.
Health Canada warned Canadians against injecting unauthorized peptides purchased online, citing risks of organ damage and infection from products misleadingly labeled 'For Research Use Only.'
Health Canada issued a public advisory warning against unauthorized injectable peptide drugs sold online for weight loss, anti-aging, and bodybuilding. Seized products include BPC-157, CJC-1295, retatrutide, and others, with cited risks of liver/kidney damage, blood clots, and cancerous tumours.
CBC investigation compares the peptide trend to historical pseudoscience, with scientists emphasizing no large-scale human trials exist for peptides sold by influencers.
The regulated peptide market is worth $50 billion and projected to double by the early 2030s. Unregulated peptides like BPC-157 and TB-500 lack rigorous human safety data and are increasingly sourced from gray-market Chinese distributors.
A new study identified a potential link between semaglutide use and a rare dermatological pain syndrome. Researchers also referenced Phase 2 retatrutide data as part of broader incretin safety analysis.
Eric Topol of Scripps Research called peptide data "woefully minuscule," warning about impurities, random dosing, and dangerous stacking of unproven compounds from gray-market sources.
In-depth AP investigation on influencers and celebrities promoting unapproved injectable peptides produced by compounding pharmacies without FDA-level scrutiny.
Clinical insights suggest GLP-1 agonists may pose extra risks for Ehlers-Danlos Syndrome patients, as delayed gastric emptying can exacerbate GI connective tissue vulnerabilities.
Physician William Meller describes treating a patient in anaphylaxis after self-injecting online peptides, and critiques RFK Jr.'s plan to move ~14 compounds off the FDA restricted list.
Investigation into men injecting BPC-157 and Thymosin Alpha-1 from unregulated internet suppliers. Doctors warn of severe allergic reactions and potential cancer risk from growth-pathway compounds.